How Medtronic (MDT) Looks After A Tough Few Months

Medtronic (MDT) has been under pressure recently, with the stock showing a negative move over the past month and past 3 months, and weaker year to date and 1 year total returns.

At a recent close of $77.96 and a market value near $99.6b, the company sits against a backdrop of mixed long term returns over 3 and 5 years that some investors may compare with its current valuation metrics.

The recent 30 day share price return of about a 10% decline and 90 day share price return of around a 24% decline point to fading momentum, which aligns with softer year to date and 1 year total shareholder returns.

If you are reassessing healthcare exposure after Medtronic's recent pullback, it could be a useful moment to broaden your search with 35 healthcare AI stocks

So with Medtronic trading at $77.96, recent returns under pressure, and some implied discount to certain valuation markers, should you see a mispriced opportunity here, or is the market already factoring in future growth?

Most Popular Narrative: 17.9% Undervalued

According to the most followed narrative, Medtronic's fair value of $95.00 sits well above the recent $77.96 close. This frames the recent weakness in a different light.

Diverse Product Portfolio: Medtronic operates across four key segments, Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes, providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).

Want to understand why this fair value stands above the current price? The narrative leans heavily on multi segment device exposure, resilient margins, and a long running cash generation profile. Curious which assumptions around growth and profitability support that $95.00 figure and the implied discount?

Result: Fair Value of $95.00 (UNDERVALUED)

However, this story can change quickly if regulatory setbacks, product recalls, or intensifying competition in diabetes and robotics hit sentiment and compress the assumed valuation gap.

Next Steps

With sentiment clearly split between recent weakness and potential upside, now is a good time to look at the numbers yourself, weigh the trade offs, and see why some investors are focusing on 6 key rewards

Looking for more investment ideas?

If Medtronic has you rethinking your next move, do not stop here, the broader market still holds plenty of angles worth your attention.

• Spot potential value early by reviewing screener containing 23 high quality undiscovered gems, where smaller, overlooked stocks come with solid fundamentals that many investors are not watching yet.
• Strengthen portfolio resilience by scanning 72 resilient stocks with low risk scores, focusing on companies with profiles that may suit a more cautious approach.
• Target quality at a discount by checking 51 high quality undervalued stocks, highlighting stocks where fundamentals and price currently appear out of sync.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.